

**UNITED STATES PATENT AND TRADEMARK OFFICE**

Examiner: SZNAIDMAN, Marcos L. Art Unit: 1628

Re: Application of: KIM, Myung-Hwa, et al.

Serial No.: 10/562,615

Filed: July 27, 2006

For: **TRICYCLIC DERIVATIVES OR  
PHARMACEUTICALLY SALTS THEREOF, THEIR  
PREPARATIONS AND PHARMACEUTICAL  
COMPOSITIONS CONTAINING THEM**

Confirmation No.: 6138

**SUPPLEMENTAL RESPONSE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

September 21, 2011

Sir:

In addition to the response submitted on September in response to the Office Action dated May 10, 2011, the following remarks and a Declaration under 37 C.F.R. § 1.132 are provided.

**REMARKS**

Reconsideration of the present application, as amended, is respectfully requested.

**A. DECLARATION UNDER 37 C.F.R. § 1.132**

As briefly mention in the response submitted on September 12, 2011, the compound of the instant claims, especially having fluoride, contains superior pharmacological efficacy and significantly reduced toxicity compared to the compound in the cited reference, Kim et al.

Tables 3-5 in the response of September 12, 2011 provides evidence where the compounds of the present invention provides unexpectedly and significantly improved efficacy compared to paclitaxel, doxorubicin, and Compound 6 of Kim et al. The non-obviousness of the present invention can also be supported by the reduced toxicity of the compounds of the present invention